Motus GI Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024 16:05 ET
|
Motus GI Holdings, Inc.
Successfully ramped up limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system; Doubled the number of active Pure-Vu System customers ordering disposable sleeves with 100% of...
Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 18, 2024 16:05 ET
|
Motus GI Holdings, Inc.
Initiated limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system, including successful UGI procedures at several leading hospital systemsThe Company is engaged in the process...
Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds
February 22, 2024 08:00 ET
|
Motus GI Holdings, Inc.
FORT LAUDERDALE, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus” or “the Company”), a medical technology company focused on improving endoscopic outcomes...
Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract
February 21, 2024 08:52 ET
|
Motus GI Holdings, Inc.
FORT LAUDERDALE, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the “Company”) (NASDAQ: MOTS), a medical technology company focused on improving endoscopic outcomes and...
Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders
February 16, 2024 16:15 ET
|
Motus GI Holdings, Inc.
FORT LAUDERDALE, Fla., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the Company”) (NASDAQ: MOTS), today announced that its special meeting of stockholders held on February 16, 2024...
Motus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation
January 30, 2024 08:00 ET
|
Motus GI Holdings, Inc.
FORT LAUDERDALE, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus GI” or “the Company”), a medical technology company focused on improving endoscopic outcomes...
Motus GI Holdings, Inc. Announces Pricing of $5.0 Million Public Offering
December 18, 2023 22:10 ET
|
Motus GI Holdings, Inc.
FORT LAUDERDALE, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus GI” or “the Company”), a medical technology company focused on improving endoscopic outcomes...
Motus GI Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023 16:05 ET
|
Motus GI Holdings, Inc.
First case performed using the new FDA cleared Pure-Vu® EVS Gastro system, and expect to initiate broader market introductions by the end of 2023Pure-Vu EVS Gastro addresses the Upper GI market, an...
Motus GI Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu® EVS Gastro
November 10, 2023 08:00 ET
|
Motus GI Holdings, Inc.
- - -The upper GI procedure was performed by Dr. Brian Hanson, gastroenterologist and Assistant Professor, Medicine, at the University of Minnesota- - -Pure-Vu EVS Gastro addresses the Upper GI...
Motus GI Announces 1-for-15 Reverse Stock Split
November 01, 2023 08:00 ET
|
Motus GI Holdings, Inc.
FORT LAUDERDALE, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes...